Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 7/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.36 |
| ▸ | LSS | P48449 | 1/20 | 0.35 |
| ▸ | PYCR1 | P32322 | 2/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | MME | P08473 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23803521 | 0.86 | RIPK1 (0.68) | RIPK1TDP1 | |
| SCHEMBL23803531 | 0.84 | RIPK1 (0.50) | RIPK1LMNAALDH1A1L3MBTL1 | |
| SCHEMBL23803517 | 0.84 | RIPK1 (0.64) | RIPK1L3MBTL1 | |
| SCHEMBL23819875 | 0.79 | RIPK1 (0.72) | RIPK1 | |
| SCHEMBL25190333 | 0.77 | RIPK1 (0.44) | RIPK1L3MBTL1 | |
| SCHEMBL23803566 | 0.76 | RIPK1 (0.50) | RIPK1 | |
| SCHEMBL17882162 | 0.76 | RIPK1 (0.68) | RIPK1TDP1 | |
| SCHEMBL23819641 | 0.75 | RIPK1 (0.68) | RIPK1MAOB | |
| SCHEMBL17882238 | 0.74 | RIPK1 (0.64) | RIPK1L3MBTL1 | |
| SCHEMBL9372536 | 0.71 | ALOX5 (0.53) | LMNAALDH1A1PYCR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12129221-B2 | Difluoro phenyl amide RIP1 inhibitor | SIRONAX LTD (KY) | 2024-10-29 | — | — | US | disclosed |
| EP-3883918-B1 | RIP1 INHIBITORS | SIRONAX LTD (KY) | 2023-07-19 | — | — | EP | disclosed |
| CN-113272272-B | RIP1 inhibitors | 圣瑞诺有限公司 | 2023-04-07 | — | — | CN | disclosed |
| US-20210284598-A1 | RIP1 Inhibitors | SIRONAX LTD (KY) | 2021-09-16 | — | — | US | disclosed |
| US-20210284598-A1 | RIP1 Inhibitors | SIRONAX LTD (KY) | 2021-09-16 | — | — | US | disclosed |
| CN-113272272-A | RIP1 inhibitors | 圣瑞诺有限公司 | 2021-08-17 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210284598-A1 | RIP1 Inhibitors | RIPK1, RIPK3, RIPK4 | RIPK1 1/4885LMNA 1572/4885ALDH1A1 3847/4885 |
| US-12129221-B2 | Difluoro phenyl amide RIP1 inhibitor | RIPK1, RIPK3, RIPK4 | RIPK1 1/4885LMNA 2445/4885ALDH1A1 3794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.